Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2019-08-21 Earnings Release
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME
Earnings Release Classification · 95% confidence The document is titled with a headline announcing 'Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317...' and is explicitly labeled as 'Regulated Information – Inside Information' and 'PRESS RELEASE'. It details the results of a clinical trial (Phase 2a study for DME) and includes commentary from the CEO and contact information for investor relations. This format strongly indicates an immediate public disclosure of material, non-public information regarding clinical trial outcomes, which is typically disseminated via an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of financial/operational results (topline data), it fits best under the Earnings Release (ER) category, which covers initial announcements of periodical results, even though this is clinical data rather than quarterly financials. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP). Given the nature of reporting clinical trial results to the market, ER is the most appropriate fit among the options for a time-sensitive operational update. Q3 2019
2019-08-21 English
OXUR transparency statement CLAY 100519 EN.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled 'Mr Thomas M. Clay and Mrs Lavinia Clay: control and voting rights Oxurion NV' and explicitly states it is a 'Transparency Statement' pursuant to Belgian transparency legislation. It details changes in the percentage of voting rights held by specific shareholders (Mr. Clay and entities controlled by him) as of specific dates (May 1, 2019). This content directly relates to notifications about changes in significant share ownership thresholds, which aligns perfectly with the definition for Major Shareholding Notification (MRQ). It is not an earnings release, a full annual report, or a proxy statement.
2019-05-10 English
OXUR transparency statement CLAY 100519 NL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Persbericht - Gereglementeerde Informatie / Transparantieverklaring" (Press Release - Regulated Information / Transparency Declaration) and details changes in share control and voting rights held by specific individuals (Mr Thomas M. Clay and Mrs Lavinia Clay) in Oxurion NV, referencing Belgian transparency legislation. This content directly relates to insider transactions or significant changes in share ownership thresholds. Since it is a formal announcement regarding shareholding changes and control, it aligns best with the 'Major Shareholding Notification' (MRQ) definition, which covers changes in significant share ownership levels crossing thresholds. It is not a Director's Dealing (DIRS) as it concerns external parties/trusts controlling shares, nor is it a general regulatory filing (RNS) because MRQ is more specific. The document length (5694 chars) is substantial enough to be the primary disclosure, not just an announcement of a report.
2019-05-10 Dutch
OXUR AGM07May2019 Proxies.pdf
Proxy Solicitation & Information Statement Classification · 19% confidence
2019-05-10 Dutch
OXUR AGM07May2019 AttendanceList.pdf
AGM Information Classification · 99% confidence The document is titled "AANWEZIGHEIDSLIJST BUITENGEWONE EN GEWONE ALGEMENE VERGADERING VAN 7 MEI 2019 OM 14:00 UUR" (Attendance List Extraordinary and Ordinary General Meeting of May 7, 2019 at 2:00 PM). This document explicitly lists shareholders, their represented shares, and attendees for a General Meeting. This content directly relates to the materials presented or used during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2019-05-10 Dutch
OXUR AGM07May2019 MeetingMinutes.PDF
AGM Information Classification · 100% confidence The document is explicitly titled "NOTULEN VAN DE GEWONE ALGEMENE VERGADERWI~G VAN AANDEELHOUDERS GEHOUDEN OP 7 MEI 2019" (Minutes of the Ordinary General Meeting of Shareholders held on May 7, 2019). It details the agenda, attendance, discussions, and the resulting resolutions (Besluiten) passed during this meeting, covering items like the approval of the annual accounts, remuneration reports, director compensation, and reappointment of directors and the auditor. This content perfectly matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although it contains elements related to remuneration (DEF 14A) and audit reports (AR), the primary nature and structure of the document are the official minutes of the AGM.
2019-05-10 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.